Oropharyngeal cancer

References

Key articles

Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 year. Cancer. 2005 May 1;103(9):1843-9.Full text  Abstract

Soo KC, Tan EH, Wee J, et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer. 2005 Aug 8;93(3):279-86.Full text  Abstract

Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78.Full text  Abstract

Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011 Jul;100(1):33-40. Abstract

Pignon JP, le Maitre A, Maillard E, et al; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009 Jul;92(1):4-14. Abstract

Posner MR, Hershock DM, Blajman CR, et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1705-15.Full text  Abstract

Mesia R, Henke M, Fortin A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb;16(2):208-20. Abstract

Guha S, Kelly CG, Guha R, et al. Intensity modulated radiation therapy (IMRT) in the treatment of squamous carcinoma of the oropharynx: an overview. J Cancer Sci Ther. 2012;4(4):77-83.Full text

Reference articles

1. Barnes L, Eveson JW, Reichart P, et al. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon, France: IARC Press; 2005.

2. Mourad M, Jetmore T, Jategaonkar AA, et al. Epidemiological trends of head and neck cancer in the United States: A SEER population study. J Oral Maxillofac Surg. 2017 May 22;75(12):2562-72.Full text  Abstract

3. Van Dyne EA, Henley SJ, Saraiya M, et al. Trends in human papillomavirus-associated cancers - United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):918-24.Full text  Abstract

4. Carvalho AL, Nishimoto IN, Califano JA, et al. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005 May 1;114(5):806-16.Full text  Abstract

5. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 year. Cancer. 2005 May 1;103(9):1843-9.Full text  Abstract

6. Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic viral-induced carcinoma? Int J Cancer. 2009 Jul 15;125(2):362-6. Abstract

7. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007 May 10;356(19):1944-56.Full text  Abstract

8. Ryerson AB, Peters ES, Coughlin SS, et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer. 2008 Nov 15;113(10 Suppl):2901-9. Abstract

9. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008 Feb 1;26(4):612-9.Full text  Abstract

10. Critchley JA, Unal B. Health effects associated with smokeless tobacco: a systematic review. Thorax. 2003 May;58(5):435-43.Full text  Abstract

11. Golechha M. Health promotion methods for smoking prevention and cessation: a comprehensive review of effectiveness and the way forward. Int J Prev Med. 2016 Jan 11;7:7.Full text  Abstract

12. Hammarstedt L, Dahlstrand H, Lindquist D, et al. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol. 2007 Sep;127(9):988-92. Abstract

13. Znaor A, Brennan P, Gajalakshmi V, et al. Independent and combined effects of tobacco smoking, chewing and alcohol drinking on the risk of oral, pharyngeal and esophageal cancers in Indian men. Int J Cancer. 2003 Jul 10;105(5):681-6.Full text  Abstract

14. Asthana S, Labani S, Kailash U, et al. Association of smokeless tobacco use and oral cancer: a systematic global review and meta-analysis. Nicotine Tob Res. 2018 May 22 [Epub ahead of print]. Abstract

15. Suk R, Mahale P, Sonawane K, et al. Trends in risks for second primary cancers associated with index human papillomavirus-associated cancers. JAMA Netw Open. 2018 Sep 7;1(5):e181999.Full text  Abstract

16. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210.Full text  Abstract

17. Baan R, Straif K, Grosse Y, et al. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007 Apr;8(4):292-3. Abstract

18. Hashibe M, Brennan P, Strange RC, et al. Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1509-17.Full text  Abstract

19. Wang X, Wang HK, McCoy JP, et al. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA. 2009 Apr;15(4):637-47.Full text  Abstract

20. Boffetta P, Hecht S, Gray N, et al. Smokeless tobacco and cancer. Lancet Oncol. 2008 Jul;9(7):667-75. Abstract

21. Chen YJ, Chang JT, Liao CT, et al. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci. 2008 Aug;99(8):1507-14.Full text  Abstract

22. Bagnardi V, Blangiardo M, La Vecchia C, et al. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer. 2001 Nov 30;85(11):1700-5.Full text  Abstract

23. Lee JJ, Jeng JH, Wang HM, et al. Univariate and multivariate analysis of prognostic significance of betel quid chewing in squamous cell carcinoma of buccal mucosa in Taiwan. J Surg Oncol. 2005 Jul 1;91(1):41-7. Abstract

24. Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702.Full text  Abstract

25. Epstein JB, Gorsky M, Cabay RJ, et al. Screening for and diagnosis of oral premalignant lesions and oropharyngeal squamous cell carcinoma: role of primary care physicians. Can Fam Physician. 2008 Jun;54(6):870-5.Full text  Abstract

26. Nguyen NP, Vos P, Moltz CC, et al. Analysis of the factors influencing dysphagia severity upon diagnosis of head and neck cancer. Br J Radiol. 2008 Sep;81(969):706-10. Abstract

27. Nguyen NP, Vos P, Lee H, et al. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer. Oncology. 2008;75(3-4):186-91. Abstract

28. Nguyen NP, North D, Smith HJ, et al. Safety and effectiveness of prophylactic gastrostomy tubes for head and neck cancer patients undergoing chemoradiation. Surg Oncol. 2006 Dec;15(4):199-203. Abstract

29. Balm AJ, van Velthuysen ML, Hoebers FJ, et al. Diagnosis and treatment of a neck node swelling suspicious for a malignancy: an algorithmic approach. Int J Surg Oncol. 2010 May 30;2010:581540.Full text  Abstract

30. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancers [internet publication].Full text

31. van den Brekel MW, Casteljins JA, Stel HV, et al. Modern imaging techniques and ultrasound-guided aspiration cytology for the assessment of neck node metastases: a prospective comparative study. Eur Arch Otorhinolaryngol. 1993;250(1):11-7. Abstract

32. Knappe M, Louw M, Gregor RT. Ultrasonography-guided fine-needle aspiration for the assessment of cervical metastases. Arch Otolaryngol Head Neck Surg. 2000 Sep;126(9):1091-6.Full text  Abstract

33. Guardiola E, Pivot X, Dassonville O, et al. Is routine triple endoscopy for head and neck carcinoma patients necessary in light of a negative chest computed tomography scan? Cancer. 2004 Nov 1;101(9):2028-33.Full text  Abstract

34. Guardiola E, Chaigneau L, Villanueva C, et al. Is there still a role for triple endoscopy as part of staging for head and neck cancer? Curr Opin Otolaryngol Head Neck Surg. 2006 Apr;14(2):85-8. Abstract

35. Garcia C, Flamen P. Role of positron emission tomography in the management of head and neck cancer in the molecular therapy era. Curr Opin Oncol. 2008 May;20(3):275-9. Abstract

36. Heron DE, Andrade RS, Beriwal S, et al. PET-CT in radiation oncology: the impact on diagnosis, treatment planning, and assessment of treatment response. Am J Clin Oncol. 2008 Aug;31(4):352-62. Abstract

37. Erdi YE. Limits of tumor detectability in nuclear medicine and PET. Mol Imaging Radionucl Ther. 2012 Apr 1;21(1):23-8.Full text  Abstract

38. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC cancer staging manual. 7th ed. New York, NY: Springer-Verlag, 2010.

39. Lenz M, Greess H, Baum U, et al. Oropharynx, oral cavity, floor of the mouth: CT or MRI. Eur J Radiol. 2000 Mar;33(3):203-15. Abstract

40. Zima AJ, Wesolowski JR, Ibrahim N, et al. Magnetic resonance imaging of oropharyngeal cancer. Top Magn Reson Imaging. 2007 Aug;18(4):237-42. Abstract

41. Hujala K, Sipilä J, Grenman R. Panendoscopy and synchronous second primary tumors in head and neck cancer patients. Eur Arch Otorhinolaryngol. 2005 Jan;262(1):17-20. Abstract

42. Miller FR, Karnad AB, Eng T, et al. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy. Head Neck. 2008 Jan;30(1):28-34.Full text  Abstract

43. Wong RJ. Current status of FDG-PET for head and neck cancer. J Surg Oncol. 2008 Jun 15;97(8):649-52. Abstract

44. Johansen J, Buus S, Loft A, et al. Prospective study of 18FDG-PET in the detection and management of patients with lymph nodes metastases to the neck from an unknown primary tumor: results from the DAHANCA-13 study. Head Neck. 2008 Apr;30(4):471-8. Abstract

45. Branstetter BF 4th, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology. 2005 May;235(2):580-6. Abstract

46. Pitchers M, Martin C. Delay in referral of oropharyngeal squamous cell carcinoma to secondary care correlates with a more advanced stage at presentation, and is associated with poorer survival. Br J Cancer. 2006 Apr 10;94(7):955-8.Full text  Abstract

47. Roosli C, Tschudi DC, Studer G, et al. Outcome of patients after treatment for a squamous cell carcinoma of the oropharynx. Laryngoscope. 2009 Mar;119(3):534-40. Abstract

48. Koivunen P, Rantala N, Hyrynkangas, et al. The impact of patient and professional diagnostic delays on survival in pharyngeal cancer. Cancer. 2001 Dec 1;92(11):2885-91.Full text  Abstract

49. Tromp DM, Brouha XD, Hordijk GJ, et al. Patient and tumour factors associated with advanced carcinomas of the head and neck. Oral Oncol. 2005 Mar;41(3):313-9. Abstract

50. van Bokhorst-de van der Schueren MA, van Leeuwen PA, Sauerwein HP, et al. Assessment of malnutrition parameters in head and neck cancer and their relation to postoperative complications. Head Neck. 1997 Aug;19(5):419-25. Abstract

51. Ho T, Zahurak M, Koch WM. Prognostic significance of presentation-to-diagnosis interval in patients with oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):45-51.Full text  Abstract

52. Ichimura K, Tanaka T. Trismus in patients with malignant tumours in the head and neck. J Laryngol Otol. 1993 Nov;107(11):1017-20. Abstract

53. Gourin CG, Watts T, Willams HT, et al. Identification of distant metastases with PET-CT in patients with suspected recurrent head and neck cancer. Laryngoscope. 2009 Apr;119(4):703-6. Abstract

54. Pantvaidya GH, Agarwal JP, Deshpande MS, et al. PET-CT in recurrent head neck cancers: a study to evaluate impact on patient management. J Surg Oncol. 2009 Oct 1;100(5):401-3. Abstract

55. Abgral R, Querellou S, Potard G, et al. Does 18-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med. 2009 Jan;50(1):24-9. Abstract

56. Connell CA, Corry J, Milner AD, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck. 2007 Nov;29(11):986-95. Abstract

57. Nahmias C, Lemmens C, Faul D, et al. Does reducing CT artifacts from dental implants influence the PET interpretation in PET/CT studies of oral cancer and head and neck cancer? J Nucl Med. 2008 Jul;49(7):1047-52.Full text  Abstract

58. Mehanna H, Olaleye O, Licitra L. Oropharyngeal cancer - is it time to change management according to human papilloma virus status? Curr Opin Otolaryngol Head Neck Surg. 2012 Apr;20(2):120-4. Abstract

59. Buglione M, Maddalo M, Corvò R, et al. Subgroup analysis according to human papillomavirus status and tumor site of a randomized phase II trial comparing cetuximab and cisplatin combined with radiation therapy for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):462-72. Abstract

60. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. Abstract

61. Epstein JB, Silverman S Jr., Epstein JD, et al. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemoluminescence and toluidine blue. Oral Oncol. 2008 Jun;44(6):538-44. [Erratum in: Oral Oncol. 2008 Jun;44(6):615.] Abstract

62. NIH National Cancer Institute. Oral cavity, pharyngeal, and laryngeal cancer screening (PDQ®) - health professional version. Apr 2019 [internet publication].Full text

63. Grégoire V, Lefebvre JL, Licitra L, et al; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v184-6.Full text  Abstract

64. Cosmidis A, Rame JP, Dassonville O, et al; Groupement d'Etudes des Tumeurs de la Tête et du Cou (GETTEC). T1-T2 N0 oropharyngeal cancers treated with surgery alone: a GETTEC study. Eur Arch Otorhinolaryngol. 2004 May;261(5):276-81. Abstract

65. Parsons JT, Mendenhall WM, Stringer SP, et al. Squamous cell carcinoma of the oropharynx: surgery, radiotherapy, or both. Cancer. 2002 Jun 1;94(11):2967-80.Full text  Abstract

66. Soo KC, Tan EH, Wee J, et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer. 2005 Aug 8;93(3):279-86.Full text  Abstract

67. Rieger J, Dickson N, Lemire R, et al. Social perception of speech in individuals with oropharyngeal reconstruction. J Psychosoc Oncol. 2006;24(4):33-51. Abstract

68. Rogers SN, Miller RD, Ali K, et al. Patients' perceived health status following primary surgery for oral and oropharyngeal cancer. Int J Oral Maxillofac Surg. 2006 Oct;35(10):913-9. Abstract

69. Nichols AC, Faquin WC, Westra WH, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2009 Feb;140(2):228-34. Abstract

70. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Apr 20;27(12):1992-8. Abstract

71. Fakhry C, Westra W, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008 Feb 20;100(4):261-9.Full text  Abstract

72. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78.Full text  Abstract

73. Yousem DM, Gad K, Tufano RP. Resectability issues with head and neck cancer. AJNR Am J Neuroradiol. 2006 Nov-Dec;27(10):2024-36.Full text  Abstract

74. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116-27.Full text  Abstract

75. McCombe D, Lyons B, Winkler R, et al. Speech and swallowing following radial forearm flap reconstruction of major soft palate defect. Br J Plast Surg. 2005 Apr;58(3):306-11. Abstract

76. Gillespie MB, Eisele DW. The uvulopalatal flap for reconstruction of the soft palate. Laryngoscope. 2000 Apr;110(4):612-5. Abstract

77. Le Scodan R, Pommier P, Ardiet JM, et al. Exclusive brachytherapy for T1 and T2 squamous cell carcinomas of the velotonsillar area: results in 44 patients. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):441-8. Abstract

78. Levendag P, Nijdam W, Noever I, et al. Brachytherapy versus surgery in carcinoma of tonsillar fossa and/or soft palate: late adverse sequelae and performance status: can we be more selective and obtain better tissue sparing? Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):713-24. Abstract

79. Erkal HS, Serin M, Amdur RJ, et al. Squamous cell carcinoma of soft palate treated with radiation therapy alone or followed by planned neck dissection. Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):359-66. Abstract

80. Kazi R, Prasad VM, Kanagalingam J, et al. Analysis of formant frequencies in patients with oral and oropharyngeal cancers treated by glossectomy. Int J Lang Commun Disord. 2007 Sep-Oct;42(5):521-32. Abstract

81. Harrison LB, Zelefsky MJ, Armstrong JG, et al. Performance status after treatment for squamous cell cancer of the base of tongue: a comparison of primary radiation therapy versus primary surgery. Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):953-7. Abstract

82. Denittis AS, Machtay M, Rosenthal DI, et al. Advanced oropharyngeal cancer treated with surgery and radiotherapy: oncologic outcome and functional assessment. Am J Otolaryngol. 2001 Sep-Oct;22(5):329-35. Abstract

83. Lim YC, Hong HJ, Baek SJ, et al. Combined surgery and postoperative radiotherapy for oropharyngeal squamous cell carcinoma in Korea: analysis of 110 cases. Int J Oral Maxillofac Surg. 2008 Dec;37(12):1099-105. Abstract

84. Nguyen NP, Vos P, Smith HJ, et al. Concurrent chemoradiation for locally advanced oropharyngeal cancer. Am J Otolaryngol. 2007 Jan-Feb;28(1):3-8. Abstract

85. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck. 1997 Oct;19(7):567-75. Abstract

86. Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011 Jul;100(1):33-40. Abstract

87. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol. 2005 Feb 20;23(6):1125-35.Full text  Abstract

88. Tao Y, Auperin A, Sire C, et al. Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007-01 phase III randomized trial. J Clin Oncol. 2018 Nov;36(31):3084-90. Abstract

89. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2018 Nov 15;393(10166):40-50. Abstract

90. Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2018 Nov 15;393(10166):51-60.Full text  Abstract

91. Bensadoun RJ, Benezery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):983-94. Abstract

92. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1161-71. [Erratum in: Int J Radiat Oncol Biol Phys 2001 Oct 1;51(2):569.] Abstract

93. Semrau R, Mueller RP, Stuetzer H, et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1308-16. Abstract

94. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant chemoradiotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004 Jan 1;22(1):69-76.Full text  Abstract

95. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6.Full text  Abstract

96. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998 Jun 18;338(25):1798-804.Full text  Abstract

97. Pignon JP, le Maitre A, Maillard E, et al; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009 Jul;92(1):4-14. Abstract

98. Posner MR, Hershock DM, Blajman CR, et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1705-15.Full text  Abstract

99. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92-8. Abstract

100. Blanchard P, Bourhis J, Lacas B, et al; Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013 Aug 10;31(23):2854-60.Full text  Abstract

101. Martins RG, Parvathaneni U, Bauman JE, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013 Apr 10;31(11):1415-21.Full text  Abstract

102. Mesia R, Henke M, Fortin A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb;16(2):208-20. Abstract

103. Burtness B, Goldwasser MA, Flood W, et al. A phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005 Dec 1;23(34):8646-54. [Erratum in: J Clin Oncol. 2006 Feb 1;24(4):724.]Full text  Abstract

104. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009 Feb 5;360(6):563-72.Full text  Abstract

105. Bumpous JM. Surgical salvage of cancer of the oropharynx after chemoradiation. Curr Oncol Rep. 2009 Mar;11(2):151-5. Abstract

106. Watkins JM, Shirai KS, Wahlquist AE, et al. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. 2009 Apr;31(4):493-502. Abstract

107. Urba S, van Herpen CM, Sahoo TP, et al. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer. 2012 Oct 1;118(19):4694-705. Abstract

108. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375(19):1856-67.Full text  Abstract

109. Harrington KJ, Ferris RL, Blumenschein G Jr, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1104-15. Abstract

110. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016 May 27;17(7):956-65. Abstract

111. Chow LQ, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016 Sep 30;34(32):3838-45.Full text  Abstract

112. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 Nov 23;394(10212):1915-28.Full text  Abstract

113. Brock PR, Maibach R, Childs M, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med. 2018 Jun 21;378(25):2376-85.Full text  Abstract

114. Meluch AA, Spigel D, Burris HA, et al. Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck. J Clin Oncol. 2009 May 20;27(15_suppl):6012.Full text

115. Mercke C, Wickart-Johansson G, Sjodin H, et al. Upfront chemotherapy and accelerated radiotherapy with EGFR inhibition for locally advanced inoperable head and neck cancer. J Clin Oncol. 2009 May 20;27(15_suppl):6040.Full text

116. Martins RG, Parvathaneni U, Bauman JE, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013;31:1415-1421.Full text  Abstract

117. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al; SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013 Jul;14(8):697-710. Abstract

118. Pang E, Delic NC, Hong A, et al. Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6∗I. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):860-5. Abstract

119. Young R, Rischin D, Fisher R, et al. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1230-7. Abstract

120. Nguyen NP, Ceizyk M, Vos P, et al. Feasibility of tomotherapy-based image-guided radiotherapy for locally advanced oropharyngeal cancer. PLoS One. 2013;8(3):e60268.Full text  Abstract

121. Lee SY, Park YM, Byeon HK, et al. Comparison of oncologic and functional outcomes after transoral robotic lateral oropharyngectomy versus conventional surgery for T1 to T3 tonsillar cancer. Head Neck. 2013 Oct 17;36(8):1138-45. Abstract

122. Lukens JN, Lin A, Gamerman V, et al. Late consequential surgical bed soft tissue necrosis in advanced oropharyngeal squamous cell carcinomas treated with transoral robotic surgery and postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Jun 10;89(5):981-8. Abstract

123. Koyfman SA, Ismaila N, Crook D, et al. Management of the neck in squamous cell carcinoma of the oral cavity and oropharynx: ASCO clinical practice guideline. J Clin Oncol. 2019 Feb 27 [Epub ahead of print].Full text  Abstract

124. Quon H, Vapiwala N, Forastiere A, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: American Society of Clinical Oncology endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline. J Clin Oncol. 2017 Oct 24;35(36):4078-90.Full text  Abstract

125. Beitler JJ, Quon H, Jones CU, et al; Expert Panel on Radiation Oncology - Head and Neck. ACR appropriateness criteria® locoregional therapy for resectable oropharyngeal squamous cell carcinomas. Head Neck. 2016 Jun 22;38(9):1299-309. Abstract

126. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010 Sep 20;28(27):4142-8. Abstract

127. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35.Full text  Abstract

128. Nguyen NP, Ly BH, Betz M, et al. Importance of age as a prognostic factor fortonsillar carcinoma. Ann Surg Oncol. 2010 Oct;17(10):2570-7. Abstract

129. Bernier J, Domenge C, Ozsahin M, et al; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945-52.Full text  Abstract

130. Guha S, Kelly CG, Guha R, et al. Intensity modulated radiation therapy (IMRT) in the treatment of squamous carcinoma of the oropharynx: an overview. J Cancer Sci Ther. 2012;4(4):77-83.Full text

131. Gupta T, Jain S, Agarwal JF, et al. Prospective assessment of patterns of failure after high-precision definitive (chemo)radiation in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):522-31. Abstract

132. Al-Mamgani A, Van Rooij P, Tans L, et al. Toxicity and outcome of intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy for oropharyngeal cancer: a matched-pair analysis. Technol Cancer Res Treat. 2013 Apr;12(2):123-30. Abstract

133. Nguyen NP, Moltz CC, Frank C, et al. Effectiveness of the cough reflex in patients with aspiration following radiation for head and neck cancer. Lung. 2007 Sep-Oct;185(5):243-8. Abstract

134. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007 Nov 1;25(31):4873-9.Full text  Abstract

135. Helson L, Okonkwo E, Anton L, et al. cis-Platinum ototoxicity. Clin Toxicol. 1978;13(4):469-78. Abstract

136. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998 Apr;77(8):1355-62.Full text  Abstract

137. Melamed LB, Selim MA, Schuchman D. Cisplatin ototoxicity in gynecologic cancer patients. A preliminary report. Cancer. 1985 Jan 1;55(1):41-3. Abstract

138. Hitchcock YJ, Tward JD, Szabo A, et al. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):779-88. Abstract

139. Jereczek-Fossa BA, Zarowski A, Milani F, et al. Radiotherapy-induced ear toxicity. Cancer Treat Rev. 2003 Oct;29(5):417-30. Abstract

140. van der Molen L, van Rossum MA, Burkhead LM, et al. A randomized preventive rehabilitation trial in advanced head and neck cancer patients treated with chemoradiotherapy: feasibility, compliance, and short-term effects. Dysphagia. 2010 Jul 11;26(2):155-70.Full text  Abstract

Use of this content is subject to our disclaimer